Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
05/2003
05/21/2003CN1419443A Continuous method for preparing pharmaceutical granules
05/21/2003CN1419437A Compositions and method for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
05/21/2003CN1419417A Carbohydrate system and a method for providing nutriton to a diabetic
05/21/2003CN1418705A Mixtur eof nutrients, prepn. method and application thereof
05/21/2003CN1418616A Cosmtics treatment using novel retinoid
05/21/2003CN1109047C Amphiapathic moleculs as cholesterol and other lipid uptake inhibitors
05/21/2003CN1108795C Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or doner, or a nitric oxide inhibitor
05/20/2003WO2003044037A2 Process for the manufacture of human mononuclear phagocytic leukocytes
05/20/2003US6566554 Including amino benzothiophenones; useful for treatment of inflammatory diseases in which the production of cytokines is involved in the pathogenesis
05/20/2003US6566543 2-arachidonylglycerol (2-AG)-an inhibitor of tumor necrosis factor-α and neuroprotector of brain in closed head injury
05/20/2003US6566506 Useful in extending the in vivo circulating life of biologically active materials
05/20/2003US6566407 Administering to a patient suffering from kidney stone calcium oxalate deposit) therapeutically effective amount of one or more crosslinked aliphatic amine polymers such as polyallylamine, polydiallylamine or polyvinylamine
05/20/2003US6566398 Method for treatment of external secretion disorders
05/20/2003US6566396 Carbetapentane tannate and chlorpheniramine tannate which are effective when administered orally for the symptomatic relief of coryza associated with the common cold, sinusitis, allergic rhinitis, and unproductive cough
05/20/2003US6566395 Methods of treating proliferative disorders
05/20/2003US6566389 For prophylaxis and therapy of tardive dyskensia
05/20/2003US6566377 Have utility as, inter alia, hypoglycemic, and anti-obesity agents.
05/20/2003US6566370 Administering decahydroisoquinoline-3-carboxylic acid derivative for therapy of migraine
05/20/2003US6566368 Aministering apomorphine or a pharmaceutically acceptable acid addition salt thereof intranasally and in an amount sufficient to induce an erection adequate for vaginal penetration but less than the amount that induces substantial nausea
05/20/2003US6566365 Method for the treatment of Flaviviridea viral infection using nucleoside analogues
05/20/2003US6566353 Method of treating malignancy associated hypercalcemia using active vitamin D analogues
05/20/2003US6566338 Administering caspase inhibitor for therapy of oral mucositis, gastrointestinal mucositis, bladder mucositis or proctitis resulting from chemotherapy or radiation therapy of cancer in an animal
05/20/2003US6566324 Preventing airway mucus production by administration of EGF-R antagonists
05/20/2003US6566081 Detection of modulator of steroid hormone activity; obtain cells, incubate with enzyme inhibitors of varying concentrations, measure the effect of each concentration on phosphatidyl inositol-3-kinase activity in cells
05/20/2003US6566080 Assay for and uses of peptide hormone receptor agonists
05/20/2003US6566065 Diagnosing schizophrenia in humans; obtain sample, analyze the methylenetetrahydrofolate reductase nucleic acid expression in sample, genotype sample, presence of mutation indicates schizophrenia
05/20/2003US6566063 Diagnosing cancer in cells; obtain cells, monitor expression of gland-specific transcription factor, compare to control, evaluate for cancer
05/20/2003US6566048 Acetyl-COA-carboxylase from Candida albicans
05/20/2003US6565891 Immunology response; mixture of minerals and vitamins
05/20/2003US6565885 Methods of spray drying pharmaceutical compositions
05/20/2003US6565869 Administering genetic engineered polypeptide
05/20/2003US6565831 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
05/15/2003WO2003041128A2 Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
05/15/2003WO2003040726A2 Screening for hepatitis c virus entry inhibitors
05/15/2003WO2003040725A2 Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen
05/15/2003WO2003040691A2 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
05/15/2003WO2003040345A2 Type 2 cytokine receptor and nucleic acids encoding same
05/15/2003WO2003040317A2 Lung cancer therapeutics and diagnostics
05/15/2003WO2003040295A2 Ion channel
05/15/2003WO2003040138A1 Dimeric compounds and their use as anti-viral agents
05/15/2003WO2003040137A1 Dimeric compounds and their use as anti-viral agents
05/15/2003WO2003040136A1 Dimeric compounds and their use as anti-viral agents
05/15/2003WO2003040135A1 Dimeric compounds and their use as anti-viral agents
05/15/2003WO2003040131A1 Aminopyrimidines and pyridines
05/15/2003WO2003040121A1 Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
05/15/2003WO2003040114A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
05/15/2003WO2003040107A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
05/15/2003WO2003039616A1 Percutaneous transluminal drug delivery device
05/15/2003WO2003039600A1 Selective treatment of il-13 expressing tumors
05/15/2003WO2003039599A1 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
05/15/2003WO2003039588A1 Pharmaceutical composition comprising factor vii polypeptides and tissue plasminogen inhibitors
05/15/2003WO2003039587A1 Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors
05/15/2003WO2003039585A1 Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
05/15/2003WO2003039578A1 Treatment of congestive heart failure
05/15/2003WO2003039573A1 TARGETING THE REVERSE MODE OF THE Na+/Ca2+ EXCHANGER FOR THE TREATMENT OF OPTIC NEUROPATHY ASSOCIATED WITH GLAUCOMA AND ISCHEMIC OPTIC NEUROPATHY
05/15/2003WO2003039572A1 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
05/15/2003WO2003039571A1 Improved use of antitumoral compound in cancer therapy
05/15/2003WO2003039561A1 Pharmaceutical composition
05/15/2003WO2003039559A1 Pharmaceutical combinatons comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical application
05/15/2003WO2003039553A1 Compositions for treatment of postmenopausal female sexual dysfunction
05/15/2003WO2003039552A1 Combination of pde4 or pde3/4 inhibitor and an anti-rheumatic drug
05/15/2003WO2003039550A1 Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
05/15/2003WO2003039548A1 Hydrazono-malonitriles
05/15/2003WO2003039536A1 Enhancement of taxane-based chemotherapy by a cdk1 antagonist
05/15/2003WO2003039535A1 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
05/15/2003WO2003039534A1 Compositions and methods for treating osteoporosis
05/15/2003WO2003039528A1 Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor
05/15/2003WO2003039525A1 Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
05/15/2003WO2003039524A1 Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
05/15/2003WO2003039521A1 Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs
05/15/2003WO2003039519A2 Dual controlled release dosage form
05/15/2003WO2003039504A1 Solid oral compositions
05/15/2003WO2003039488A2 A method for treating inflammatory bowel disease
05/15/2003WO2003039484A2 Novel compositions and methods for cancer
05/15/2003WO2003039478A2 Method and apparatus for the stimulation of hair growth
05/15/2003WO2003039476A2 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
05/15/2003WO2003039475A2 Methods of identifying and using modulators of fractalkine receptor
05/15/2003WO2003039473A2 Method for treating or preventing inflammatory diseases
05/15/2003WO2003039469A2 Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
05/15/2003WO2003039466A2 Method of treating estrogen responsive breast cancer
05/15/2003WO2003039462A2 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
05/15/2003WO2003039455A2 Methods of treating endometreosis
05/15/2003WO2003039452A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003WO2003039449A2 Modulation of dopaminergic neurons
05/15/2003WO2003039437A2 Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel
05/15/2003WO2003039436A2 Pharmaceutical compositions containing oxybutynin
05/15/2003WO2003039434A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
05/15/2003WO2003039418A1 Compositions for the treatment of infectious diseases
05/15/2003WO2003039404A2 Methods for treating ocular neovascular diseases
05/15/2003WO2003039342A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
05/15/2003WO2003039341A2 Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804
05/15/2003WO2003039231A2 Compounds and methods for treating transplant rejection
05/15/2003WO2002102169A3 Synthetic fat composition
05/15/2003WO2002100836A3 Compounds, compositions and methods for modulating beta-amyloid production
05/15/2003WO2002097032A3 Proteins associated with cell growth, differentiation, and death
05/15/2003WO2002094856A3 Gpe analogs and peptidomimetics
05/15/2003WO2002083926A3 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
05/15/2003WO2002068056A3 Combination comprising a 1,4-dioxonaphathalene compound and ribenoside
05/15/2003WO2002064795A3 Putative human enzymes
05/15/2003WO2002064046A3 A compound and method of treatment for fungal pathologies of the oral cavity
1 ... 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 ... 1151